News - 2020
Check out the posts below to learn the latest updates on our progress
- November 11 2020EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care “rPOC” Subcutaneous CAR-T Platform at the SITC 35th Anniversary Annual Meeting & Pre-ConferencePR Newswire
- November 9 2020Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regressionSITC 35th Anniversary Annual Meeting & Pre-Conference (virtual)
- October 19 2020Logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumorsAACR Tumor Immunology & Immunotherapy 2020
- October 19 2020Dr. Sid Kerkar Joins EXUMA Biotech as Vice President Oncology, R&D, Company Presents Data on HER2-Targeting CAR-T at AACR Tumor Immunology and Immunotherapy ConferencePR Newswire
- October 7 2020Communicating Your Strategic PlanCFO Thought Leader
- September 24 2020Speeding the Delivery of CAR-T Therapies While Cutting the CostThe BIO Report
- August 10 2020Expanding Access to CAR-T: Dr. Greg FrostPharmExec.com
- August 3 2020How Big Data Is Accelerating EXUMA Biotech In The Race To Rapid CAR-T TherapyBioProcess Online
- June 16 2020EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of DirectorsPR Newswire
- May 12 2020Let’s Get the CAR-T StartedLongevity Technology